| Parameter . | Final Estimate . | Units . |
|---|---|---|
| r2a | 0.947 | … |
| Econb | 8.809 | Log10 PFU/mL |
| EC50 RBVc | 833.0 | µg/mL |
| m1d | 1.074 | … |
| EC50IFN alfae | 5761.0 | IU/mL |
| m2f | 0.6219 | … |
| αg | 265.5 (85.88–445.1h) | … |
| Parameter . | Final Estimate . | Units . |
|---|---|---|
| r2a | 0.947 | … |
| Econb | 8.809 | Log10 PFU/mL |
| EC50 RBVc | 833.0 | µg/mL |
| m1d | 1.074 | … |
| EC50IFN alfae | 5761.0 | IU/mL |
| m2f | 0.6219 | … |
| αg | 265.5 (85.88–445.1h) | … |
Abbreviations: IFN, interferon; PFU, plaque-forming units; RBV, ribavirin.
ar2 is coefficient of determination that quantifies goodness of fit.
bEcon is a measure of effect (or response) of the control.
cEC50 RBV is the concentration of drug resulting in half maximal effect of RBV.
dm1 is the Hill constant for RBV.
e EC50 IFN α is the concentration of drug resulting in half maximal effect of IFN alfa.
fm2 is the Hill constant for IFN alfa.
gα is the interaction parameter.
h 95% confidence interval.
| Parameter . | Final Estimate . | Units . |
|---|---|---|
| r2a | 0.947 | … |
| Econb | 8.809 | Log10 PFU/mL |
| EC50 RBVc | 833.0 | µg/mL |
| m1d | 1.074 | … |
| EC50IFN alfae | 5761.0 | IU/mL |
| m2f | 0.6219 | … |
| αg | 265.5 (85.88–445.1h) | … |
| Parameter . | Final Estimate . | Units . |
|---|---|---|
| r2a | 0.947 | … |
| Econb | 8.809 | Log10 PFU/mL |
| EC50 RBVc | 833.0 | µg/mL |
| m1d | 1.074 | … |
| EC50IFN alfae | 5761.0 | IU/mL |
| m2f | 0.6219 | … |
| αg | 265.5 (85.88–445.1h) | … |
Abbreviations: IFN, interferon; PFU, plaque-forming units; RBV, ribavirin.
ar2 is coefficient of determination that quantifies goodness of fit.
bEcon is a measure of effect (or response) of the control.
cEC50 RBV is the concentration of drug resulting in half maximal effect of RBV.
dm1 is the Hill constant for RBV.
e EC50 IFN α is the concentration of drug resulting in half maximal effect of IFN alfa.
fm2 is the Hill constant for IFN alfa.
gα is the interaction parameter.
h 95% confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
